Vevye is a prescription cyclosporine 0.1% eye drop FDA-approved in May 2023 for the signs and symptoms of dry eye disease in adults. It targets chronic ocular surface inflammation rather than just masking symptoms with artificial lubrication. Harrow Eye LLC distributes it across the United States.
Cyclosporine has treated dry eye for over 20 years, but Vevye delivers the highest ophthalmic concentration (0.1%) in a water-free semi-fluorinated alkane vehicle. The water-free formula eliminates pH and osmolarity, the primary causes of burning with older drops. Clinical trials show 99.8% of patients report no or only mild burning. The drug promotes corneal healing in as little as 15 days.
This review covers how Vevye works, what clinical trials show about its effectiveness, what real users and prescribers report, how it compares to Restasis and Cequa, what the side effects look like, and whether this prescription drop is worth pursuing for chronic dry eye disease management.
What Are Vevye Eye Drops?
Vevye is a prescription cyclosporine ophthalmic solution (0.1%) FDA-approved on May 30, 2023 for the treatment of the signs and symptoms of dry eye disease in adults. Here’s the thing: it doesn’t just mask symptoms with artificial lubrication. It targets the root cause. chronic ocular surface inflammation. at the cellular level.
Developed by Novaliq GmbH (Heidelberg, Germany) and distributed in the United States by Harrow Eye LLC (Nashville, TN), Vevye entered the market as the highest-concentration ophthalmic cyclosporine product to receive FDA clearance. The drug is pronounced ‘vee-vye.’
Dry eye disease (DED) is an inflammatory ocular surface disorder affecting millions of Americans. Chronic DED causes progressive corneal surface damage. Left untreated, that damage leads to visual impairment and worsening symptoms including stinging, burning, and blurred vision.
Cyclosporine is a calcineurin inhibitor immunosuppressant that has been used to treat dry eye disease for over 20 years. Vevye delivers it at 0.1% concentration. That’s the highest in any FDA-approved ophthalmic cyclosporine product currently on the market.
What sets Vevye apart isn’t just the concentration. it’s the vehicle. Restasis and Cequa dissolve cyclosporine in water-based formulations. Vevye dissolves it in perfluorobutylpentane, a water-free semi-fluorinated alkane that enhances absorption and eliminates the stinging caused by the pH and osmolarity found in water-based drops.
Vevye is FDA-approved for adults with dry eye disease; safety and effectiveness in patients under 18 years have not been established. A prescriber evaluates candidacy through an eye exam, symptom review, medical history, and a look at what treatments have already been tried.
Prescribers often test tear quality, thickness, or volume before recommending Vevye. Patients with noticeable corneal surface damage and low tear production scores are typically strong candidates. The drug is indicated for signs. visible damage. and symptoms. what the patient feels. alike.
Most insurance plans require documented trial and failure of both Restasis (cyclosporine 0.05%) and Xiidra (lifitegrast) before authorizing Vevye. In other words: patients who’ve tried the older options and haven’t responded are often the primary candidates for a Vevye prescription.
How Do Vevye Eye Drops Work?
Vevye works by delivering cyclosporine, a calcineurin inhibitor that blocks overactive immune cell signals, reducing T-cell-driven inflammation on the ocular surface and in the meibomian glands responsible for tear production. By interrupting this inflammatory cascade, the drug allows the tear film to recover.
Applied topically, very little cyclosporine reaches the bloodstream. So what does that mean for safety? The local action limits systemic side effects. a meaningful distinction from oral cyclosporine, which suppresses the entire immune system and carries substantial systemic risks. The eye drop acts where it’s needed and stays there.
By calming ocular surface inflammation, Vevye helps eyes produce more natural tears and improves the quality of the tear film. The treatment addresses both signs (measurable changes like corneal staining and tear production scores) and symptoms (patient-reported discomfort) of dry eye disease.
What Makes Vevye’s Water-Free Formula Different?
Vevye uses EyeSol, a water-free vehicle based on perfluorobutylpentane (a semi-fluorinated alkane), which eliminates pH and osmolarity. the two primary causes of burning and stinging with traditional water-based eye drops. No water means no associated chemical properties that irritate the eye on contact.
And the tolerability result is striking. In clinical trials, 99.8% of patients reported no or only mild burning/stinging when applying Vevye. The formula contains no oils, surfactants, or preservatives. three additional common sources of irritation found in competing cyclosporine products.
The water-free vehicle also drives enhanced corneal absorption. Cyclosporine penetrates the corneal surface more efficiently in a semi-fluorinated alkane environment than in an aqueous emulsion. The result: a more concentrated effect at the site of inflammation and a longer-lasting therapeutic action.
Cyclosporine inhibits calcineurin, a protein that T-cells need to activate and release inflammatory cytokines. Blocking calcineurin silences the signaling cascade that sustains chronic ocular surface inflammation. the underlying mechanism of dry eye disease.
Here’s why this matters: overactive T-cells on the corneal surface release cytokines that damage the epithelium and disrupt tear-producing glands. Chronic exposure causes progressive corneal surface damage. The damage worsens symptoms and reduces tear secretion, creating a self-perpetuating inflammatory cycle. Cyclosporine breaks that cycle.
What Are the Ingredients in Vevye?
Vevye contains cyclosporine 0.1% (1 mg/mL) as the active ingredient. the highest concentration in any FDA-approved ophthalmic cyclosporine product. Each drop (approximately 0.01 mL) delivers 0.01 mg of cyclosporine directly to the ocular surface.
The inactive ingredients are perfluorobutylpentane (the water-free solvent vehicle) and ethanol (anhydrous). The solution contains no water, no antimicrobial preservatives, no oils, and no surfactants. In fact, this formulation is as notable for what it excludes as for what it includes. all common sources of ocular irritation are absent.
Vevye is supplied as 2 mL of sterile, clear, colorless solution in a 5 mL squeezable transparent polypropylene bottle with a polyethylene tip. One bottle lasts approximately 30 days when used as directed. one drop per eye, twice daily.
Vevye Ingredients:
- Active: cyclosporine 0.1% (1 mg/mL)
- Vehicle: perfluorobutylpentane (semi-fluorinated alkane)
- Ethanol (anhydrous)
- No water, no preservatives, no oils, no surfactants
Perfluorobutylpentane is a semi-fluorinated alkane (SFA). an inert, biocompatible fluorinated compound that replaces water entirely as the solvent in Vevye. SFAs spread evenly over the ocular surface, don’t evaporate quickly, and carry no pH or osmolarity.
Think of it this way: water-based formulations require preservatives to stay sterile, and they carry pH and osmolarity that sting on contact with the eye. SFA vehicles need no preservatives, carry no ionic load, and spread uniformly across the cornea. offering a fundamentally different delivery experience than any aqueous eye drop.
What Do Vevye Reviews Say?
Vevye is broadly noted for superior tolerability and effectiveness compared to older cyclosporine eye drops. Patient reviews and prescriber accounts consistently highlight the water-free formula as a key differentiator in comfort and treatment adherence.
Dr. Lauren Zimski, an ophthalmologist in Denver, reports that no patients have discontinued Vevye due to side effects. a remarkable outcome given the dropout rates associated with Restasis. She prescribes it widely and has personally used it. Her patients prefer Vevye over other anti-inflammatory eye drops for both tolerability and results.
The CEO of Harrow Eye (the distributor) noted that many patients are entering their sixth refill cycle. In the 52-week OLE study, only 1 of 202 patients discontinued due to an adverse event (mild burning/stinging). Adherence in long-term dry eye treatment is typically poor. this data stands out sharply.
What Are the Positive Experiences with Vevye?
Users frequently report symptom relief within two weeks of starting Vevye. Dr. Zimski notes that Vevye begins working within two weeks, unlike Restasis, which often takes months to become effective. and that difference in onset drives substantial patient satisfaction.
One representative patient review: ‘My eyes have hurt for years and now in less than a month they feel so much better.’ This pattern of rapid, meaningful relief appears across multiple accounts. For patients with chronic dry eye pain, a two-week turnaround represents a dramatic quality-of-life shift.
The 12-month OLE study provides the strongest long-term positive data point: an average 98% increase in tear production across participants, with statistically significant improvement in all efficacy endpoints including corneal staining, tear production, and patient-reported symptom scores.
Key Positive Outcomes Reported:
- Symptom relief within two weeks of starting treatment
- 98% average increase in tear production over 12 months
- High long-term adherence. patients entering their 6th refill cycle
- Only 1 of 202 patients in 52-week study discontinued due to side effects
What Are the Common Complaints About Vevye?
The most consistent complaint? The dropper. Multiple users cite a short tip and a runny, fast-flowing formula that makes dosing difficult to control. Several users report wasting product due to the bottle mechanics. which is significant given the cost.
Some users also report no drastic change compared to Restasis after months of use, suggesting individual response to Vevye varies. The drug isn’t universally superior for every patient. While clinical trials show superiority to placebo, head-to-head data against Restasis in individual patients is limited.
Does Vevye Actually Work for Dry Eye Disease?
Yes. Vevye is the first and only cyclosporine ophthalmic solution with efficacy demonstrated after 4 weeks of treatment. Two phase 3 clinical trials (CYS-002 and CYS-004) and a 12-month open-label extension study all confirm statistically significant improvements in tear production and ocular surface health.
In CYS-004, the pivotal trial, 11% of Vevye patients achieved a clinically meaningful ≥10mm increase in tear production by Day 29, compared to 7% of vehicle-control patients (p=0.05). Corneal staining scores and symptom scores showed statistically significant improvement across both studies.
Dr. John D. Sheppard, MD, MMSc, FACS, professor of ophthalmology at Eastern Virginia Medical School, put it plainly: ‘VEVYE addresses the well-documented underlying inflammatory root cause of dry eye disease, repeatedly demonstrating early and clinically meaningful efficacy upon both signs and symptoms.’
What Did Clinical Trials Show About Vevye’s Effectiveness?
CYS-002 (exploratory phase 3) showed 8% of Vevye patients vs 0% of vehicle patients achieved a ≥10mm increase in Schirmer tear test scores at Day 29 (difference 7.8%, 95% CI 0.5%-15%; p=0.04).
The 52-week ESSENCE-2 open-label extension study enrolled 202 patients who used Vevye twice daily for one year. Of 175 completers, the most common adverse event was mild instillation site pain (6.5%). Seven serious adverse events occurred during the study. all were nonocular, assessed as unrelated to Vevye, and resolved by study end. Published in Cornea journal (2024) by Wirta et al.
Dr. Laura M. Periman, MD, director of dry eye services at Periman Eye Institute, described the OLE results: ‘The most impressive data point was that only one patient stopped using Vevye because of an ocular adverse event, which was mild burning and stinging.’ Tolerability drives real-world efficacy. patients continue using treatments that don’t hurt.
Vevye Clinical Trial Results Summary:
| Study | Metric | Vevye | Vehicle/Placebo |
|---|---|---|---|
| CYS-002 (Day 29) | ≥10mm tear increase | 8% | 0% |
| CYS-004 (Day 29) | ≥10mm tear increase | 11% | 7% |
| OLE 12-month | Avg. tear production increase | 98% | N/A (open-label) |
| OLE 12-month | Discontinuations (ocular AE) | 1/202 | N/A |
How Fast Does Vevye Start to Work?
Vevye promotes corneal healing in as little as 15 days in clinical studies. faster than any other FDA-approved ophthalmic cyclosporine. Corneal staining improvement emerges early and stabilizes over time per the 12-month OLE data.
Compare that to Restasis, which often requires months of consistent use before noticeable clinical benefit appears. Vevye’s water-free vehicle allows faster and deeper corneal penetration of cyclosporine. That’s likely why the timeline is so compressed. Prescribers consistently cite the two-week onset as a primary reason patients prefer Vevye over its predecessors.
What Are the Side Effects of Vevye?
Vevye carries a mild side effect profile; the most common adverse events are eye irritation (8% of patients) and temporary blurred vision (3% of patients). Both are typically mild and don’t require discontinuation in most cases.
Eye infections represent the most serious risk. but only with improper use. Contamination occurs when the bottle tip touches the eye, fingers, or any other surface. Signs of infection include eye redness, itching, discharge, swollen eyelids, or fever. Immediate contact with a healthcare provider is warranted if these symptoms appear.
Vevye Side Effects:
- Eye irritation (8%)
- Temporary blurred vision (3%)
- Instillation site pain. mild (6.5% in 52-week study)
- Risk of infection if dropper tip contacts any surface
What Are the Most Common Side Effects of Vevye?
Eye irritation affects approximately 8% of Vevye users; temporary blurred vision affects 3%. In the 52-week OLE study, mild instillation site pain was the most common adverse event, occurring in 6.5% of the 202 participants.
In clinical trials, 99.8% of patients reported no or only mild burning/stinging when applying Vevye. In a 12-month study, only one patient stopped using the drug because of a side effect (mild burning/stinging). That’s a stark contrast to Restasis, where burning on instillation is a well-documented dropout driver.
Who Should Avoid Using Vevye?
Patients allergic to cyclosporine should not use Vevye; beyond cyclosporine allergy, no contraindications are listed in the FDA prescribing information. The drug carries no boxed warnings as of the most recent label update (February 2026).
Safety and effectiveness in pediatric patients under 18 years have not been established. Vevye is approved for adult use only. The prescribing information does not specify restrictions for pregnancy or lactation beyond standard guidance to consult a healthcare provider.
Contact lens wearers must remove lenses before applying Vevye. The drops should not be administered while contact lenses are in place. Lenses may be reinserted 15 minutes following application, unless a healthcare provider specifies otherwise.
How Do You Use Vevye Eye Drops?
Vevye is instilled as one drop in each eye twice daily, approximately 12 hours apart. One bottle contains 2 mL of solution and provides approximately 30 days of treatment when used as directed.
Before each use, wash hands thoroughly. Don’t touch the dropper tip to the eye, fingers, or any surface. contamination can cause serious eye infections. After applying each dose, recap the bottle immediately. If the tamper-evident ring was intact at first opening, it remains on the bottle neck after opening.
When using Vevye alongside other eye drops, wait at least 15 minutes between products. This spacing prevents dilution of active ingredients and ensures proper absorption of each medication.
How to Use Vevye:
- Wash hands thoroughly before handling the bottle.
- Remove contact lenses if worn.
- Tilt head back and pull down lower eyelid to create a pocket.
- Instill one drop of Vevye into the pocket. Do not touch the tip to the eye or any surface.
- Close eye gently for one minute.
- Wait 15 minutes before reinserting contact lenses.
- Repeat in the other eye.
- Recap bottle immediately after use.
The FDA-approved dosage of Vevye is one drop in each eye approximately 12 hours apart, twice daily. Each drop delivers approximately 0.01 mL of solution, containing 0.01 mg of cyclosporine.
Store Vevye at room temperature between 59°F and 77°F (15°C and 25°C) in a cool, dry location protected from light. Do not freeze or refrigerate. Check that the tamper-evident ring is intact before the first use. don’t use the product if the ring is broken.
Can You Wear Contact Lenses with Vevye?
No. Vevye must not be administered while wearing contact lenses; lenses must be removed before each application. The official prescribing information explicitly prohibits lens use during instillation.
After applying Vevye, wait 15 minutes before reinserting contact lenses. This waiting period allows the drug to absorb into the ocular surface without interference from lens material. A healthcare provider may specify different timing in individual cases.
How Does Vevye Compare to Other Cyclosporine Eye Drops?
Vevye contains 0.1% cyclosporine in a water-free semi-fluorinated alkane vehicle. the highest concentration and the most tolerant formulation among FDA-approved ophthalmic cyclosporine products. Restasis has 0.05%; Cequa has 0.09%; both use water-based vehicles.
Vevye’s water-free formulation eliminates pH and osmolarity, the primary drivers of burning and stinging with Restasis and Cequa. Dr. Zimski and other prescribers consistently report that patients who switched to Vevye prefer it for tolerability. and adherence improves when eye drops don’t hurt.
Cyclosporine Eye Drop Comparison:
| Product | Concentration | Vehicle | Preservative-Free | Onset |
|---|---|---|---|---|
| Vevye | 0.1% | Water-free SFA | Yes | ~2 weeks |
| Cequa | 0.09% | Nano-micellar aqueous | Yes | Weeks to months |
| Restasis | 0.05% | Water-based emulsion | No | Months |
How Does Vevye Compare to Restasis?
Restasis contains 0.05% cyclosporine in a water-based emulsion. Vevye delivers 0.1% in a preservative-free, water-free vehicle. double the concentration in a formula that produces far less stinging on instillation. Most prescribers who’ve worked with both report that patients strongly prefer Vevye for comfort.
Insurance commonly places Restasis as a required prior step before Vevye is authorized. Patients who try Restasis and either fail to respond or can’t tolerate the burning are the primary Vevye candidates. Vevye works within two weeks; Restasis frequently requires months of twice-daily use before clinical benefit appears.
Vevye vs Restasis Quick Comparison:
| Feature | Vevye | Restasis |
|---|---|---|
| Cyclosporine concentration | 0.1% | 0.05% |
| Vehicle | Water-free SFA | Water-based emulsion |
| Preservative-free | Yes | No |
| Onset of action | ~2 weeks | Months |
| Stinging on instillation | Minimal (99.8% mild/none) | Common complaint |
Cequa contains 0.09% cyclosporine in a nano-micellar aqueous solution. Vevye has 0.1% cyclosporine in a water-free SFA vehicle. marginally higher concentration with an anhydrous formula that enhances corneal penetration and eliminates pH- and osmolarity-related stinging.
Both Vevye and Cequa are preservative-free, a step up from Restasis. Cequa’s water-based vehicle still carries pH and osmolarity values that can cause stinging. Vevye’s water-free formulation eliminates both properties entirely. Head-to-head clinical trial data comparing Vevye directly to Cequa is limited; prescribers rely on tolerability reports and formulation science to guide their choice.
How Much Does Vevye Cost?
Vevye is a prescription-only drug; out-of-pocket cost depends on insurance coverage, and prior authorization is typically required before the plan will cover the prescription. Harrow Eye offers patient savings programs to reduce cost for eligible patients.
For insurance purposes, Vevye coverage is authorized for an initial period of 1 year, with reauthorization also covering 1-year increments. Reauthorization requires demonstrated positive clinical response. either increased tear production or measurable improvement in dry eye symptoms per the prescribing provider’s assessment.
Is Vevye Covered by Insurance?
Most insurance plans require documented diagnosis of dry eye disease AND trial and failure of. or contraindication to. both Restasis (cyclosporine 0.05%) and Xiidra (lifitegrast) before authorizing coverage for Vevye.
Reauthorization requires continued positive clinical response. Coverage is not granted for indications not listed in the coverage policy. Off-label use. including use in pediatric patients. isn’t covered. Patients should ask their prescriber’s office to submit a prior authorization request on their behalf.
Is Vevye Worth the Price?
Vevye’s 12-month OLE study showed only 1 patient discontinued due to side effects out of 202 enrolled. a testament to the drug’s tolerability, which directly drives the long-term adherence that makes dry eye treatment effective.
For patients who failed Restasis for months with no results, Vevye’s two-week onset and 98% average increase in tear production over 12 months represent meaningful clinical value. Better adherence because the drops don’t burn translates to better outcomes over time. The higher cost, if not fully covered by insurance, may be offset by savings programs and the practical advantage of a treatment patients actually continue using.
Where Can You Buy Vevye Eye Drops?
Vevye is a prescription-only medication; a visit to an eye care specialist is required before the drug can be dispensed. The specialist examines the patient’s eyes, confirms a dry eye diagnosis, and writes a prescription. Vevye cannot be purchased over the counter.
With a valid prescription, Vevye is available at retail pharmacies. Patients may also work with their prescriber to access patient savings programs or copay assistance cards offered by Harrow Eye to reduce out-of-pocket cost.
Is Vevye Legit and FDA Approved?
Yes. Vevye received FDA approval on May 30, 2023 for the treatment of signs and symptoms of dry eye disease. it’s a legitimate prescription pharmaceutical, not a supplement or unregulated product.
Vevye is backed by multiple published clinical trials: CYS-002, CYS-004 (pivotal phase 3), and the ESSENCE-2 OLE study, published in Cornea journal (2024, Wirta et al.). The drug was developed by Novaliq GmbH (Germany) and is endorsed by prominent ophthalmologists including Dr. John D. Sheppard (Eastern Virginia Medical School) and Dr. Laura M. Periman (Periman Eye Institute).
Vevye is manufactured by Alliance Medical Products for Novaliq GmbH and distributed by Harrow Eye LLC, a publicly traded ophthalmic pharmaceutical company headquartered in Nashville, TN. The prescribing label was most recently updated in February 2026 with revised dosage administration guidance (Section 2.2).
Should You Try Vevye Eye Drops?
Vevye is a strong option for adults with moderate-to-severe dry eye disease. particularly those who’ve failed or can’t tolerate Restasis or Cequa. Faster onset, the highest cyclosporine concentration available, and superior tolerability distinguish it from every other ophthalmic cyclosporine on the market.
The good news? Best candidates are adults with a confirmed dry eye diagnosis who’ve already tried OTC lubricants without adequate relief. Dr. Zimski reports treating patients with severe inflammation who failed multiple other eye drops and responded to Vevye. the drug offers a meaningful option for difficult-to-treat cases.
Bottom line: Vevye should only be used under prescription from an eye care specialist. The prescriber confirms diagnosis, screens for cyclosporine allergy, and navigates prior authorization with the insurer if needed. For anyone stuck in a cycle of burning drops that don’t work, Vevye represents a legitimate next step worth discussing with an eye doctor.